Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12077MR)

This product GTTS-WQ12077MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12077MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3059MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ9626MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ9921MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ9888MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ5878MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ5091MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ295MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ5298MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW